Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by HILIQUIN, P.
Right arrow Articles by MENKÈS, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HILIQUIN, P.
Right arrow Articles by MENKÈS, C. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 British Society for Rheumatology

other

OCCURRENCE OF PULMONARY COMPLICATIONS DURING METHOTREXATE THERAPY IN RHEUMATOID ARTHRITIS

P. HILIQUIN, M. RENOUX, S. PERROT, X. PUÉCHAL and C. J. MENKÈS

Service de Rhumatologie A, Hôopital Cochin, and Université René Descartes Paris, France

Correspondence to: Correspondence to: C. J. Menkès, Service de Rhumatologie A, Hôpital Cochin, 27 rue de Faubourg Saint-Jacques, 75679 Paris Cedex 14, France

Treatment with methotrexate (MTX) in rheumatoid arthritis (RA) can lead to severe side-effects, especially pulmonary and haematological complications. The aim of this retrospective study was to evaluate, during a 6 yr period, the prevalence and severity of bronchopulmonary side-effects in RA patients treated with MTX. A cohort of 130 RA in-patients (106 women, 24 men) treated with MTX was studied for the occurrence of respiratory adverse events. Adverse bronchopulmonary side-effects were observed in 12 patients (two men, 10 women), with a mean disease duration of 15 yr. Only three patients had previously suffered from pulmonary disease. MTX treatment duration was between 1 month and 4.5 yr. The diagnosis was that of hypersensitivity pneumonitis (HSP) in four cases, non-HSP pneumonitis in five patients with one case of Pneumocystis carinii infection, and bronchitis in three cases. The initial respiratory symptoms were not discriminatory between the different conditions. Risk factors were not identified for the occurrence of HSP. HSP always occurred in the first 5 months of treatment. Two patients with HSP died, and another patient with opportunistic infection underwent tracheostomy. HSP represents a potentially lethal side-effect in RA patients treated with MTX. Improved education of patients and physicians should certainly lead to a reduction of both the prevalence and severity of pulmonary side-effects during MTX therapy in RA.

KEY WORDS: Methotrexate, Pneumonitis, Alveolitis, Hypersensitivity, Infection


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
C. T. Ebeo, M. R. Girish, R. P. Byrd, T. M. Roy, and J. B. Mehta
Methotrexate-Induced Pulmonary Lymphoma
Chest, June 1, 2003; 123(6): 2150 - 2153.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. K. Dawson, D. R. Graham, J. Desmond, H. E. Fewins, and M. P. Lynch
Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests
Rheumatology, March 1, 2002; 41(3): 262 - 267.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.